Cargando…
The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent
TW-37 is a novel, potent and non-peptide Bcl-2 small-molecule inhibitor. Its activity in colorectal cancer (CRC) cells is studied. In both HCT-116 cells and primary human colon cancer cells, treatment with TW-37 at only nM concentration efficiently inhibited cell survival and proliferation. TW-37 al...
Autores principales: | Lei, Shun, Ding, Yao, Fu, Yun, Wu, Shuang, Xie, Xiong, Wang, Cancan, Liang, Houjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655484/ https://www.ncbi.nlm.nih.gov/pubmed/29065135 http://dx.doi.org/10.1371/journal.pone.0184501 |
Ejemplares similares
-
Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021) -
Antitumor effect of TW-37, a BH3 mimetic in human oral cancer
por: Ahn, Chi-Hyun, et al.
Publicado: (2019) -
The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines
por: Klenke, Stefanie, et al.
Publicado: (2019) -
Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016) -
Overexpression of TwSQS, TwSE, and TwOSC Regulates Celastrol Accumulation in Cambial Meristematic Cells and Dedifferentiated Cells
por: Song, Yadi, et al.
Publicado: (2022)